Wenzel, Sally
Castro, Mario
Corren, Jonathan
Maspero, Jorge
Wang, Lin
Zhang, Bingzhi
Pirozzi, Gianluca
Sutherland, E Rand
Evans, Robert R
Joish, Vijay N
Eckert, Laurent
Graham, Neil M H
Stahl, Neil
Yancopoulos, George D
Louis-Tisserand, Mariana
Teper, Ariel
Clinical trials referenced in this document:
Documents that mention this clinical trial
Documents that mention this clinical trial
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
https://doi.org/10.1016/s0140-6736(16)30307-5
Documents that mention this clinical trial
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
https://doi.org/10.1016/s0140-6736(16)30307-5
S135 Dupilumab efficacy vs standard of care in patients with uncontrolled, persistent asthma – a meta analysis
https://doi.org/10.1136/thorax-2020-btsabstracts.140
Documents that mention this clinical trial
S49 Dupilumab improves lung function across baseline disease characteristics in patients with evidence of type 2 inflammation at baseline: the LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2019-btsabstracts2019.55
S86 Long-term assessment of exacerbations and lung function in the LIBERTY ASTHMA TRAVERSE study, stratified by lung function improvements at the end of the phase 3 LIBERTY ASTHMA QUEST parent study
https://doi.org/10.1136/thorax-2021-btsabstracts.92
S118 Dupilumab efficacy is not affected by prior asthma exacerbation status in LIBERTY ASTHMA TRAVERSE open-label extension study
https://doi.org/10.1136/thorax-2023-btsabstracts.124
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
https://doi.org/10.1016/s0140-6736(16)30307-5
P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2018-212555.202
S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2018-212555.84
S127 Relation between change in type 2 biomarker levels and efficacy outcomes in patients with asthma treated with dupilumab
https://doi.org/10.1136/thorax-2022-btsabstracts.133
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
https://doi.org/10.1007/s12325-018-0702-4
S31 Dupilumab reduces severe exacerbations across baseline disease characteristics in patients with elevated baseline type 2 biomarkers: the LIBERTY ASTHMA QUEST study
https://doi.org/10.1136/thorax-2019-btsabstracts2019.37
S128 Baseline characteristics of patients with asthma treated with dupilumab in a real-world setting: results from the RAPID registry
https://doi.org/10.1136/thorax-2022-btsabstracts.134
P124 Stability of fractional exhaled nitric oxide levels as a biomarker in patients with uncontrolled asthma
https://doi.org/10.1136/thorax-2023-btsabstracts.276
S135 Dupilumab efficacy vs standard of care in patients with uncontrolled, persistent asthma – a meta analysis
https://doi.org/10.1136/thorax-2020-btsabstracts.140
S84 Long-term efficacy of dupilumab: 3-year data of QUEST patients with moderate-to-severe asthma enrolled in LIBERTY ASTHMA TRAVERSE
https://doi.org/10.1136/thorax-2021-btsabstracts.90
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
https://doi.org/10.1007/s40257-020-00577-1
This article is maintained by: Elsevier
Article Title: Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(16)30307-5
CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(16)30311-7
Content Type: article
Copyright: © 2016 Elsevier Ltd. All rights reserved.